GlassScriptPhysician profile
Amanda Pullee
NPI 1992239024
$1,875.99
in general payments reported to CMS, 2019-2025
16 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $772 · 2022: $65.10 · 2023: $200 · 2024: $483 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.30 | 2021-2024 | Wegovy |
| Abbvie INC. | $451.99 | 2021-2024 | |
| Amgen INC. | $234.91 | 2025 | Repatha |
| Madrigal Pharmaceuticals | $121.76 | 2025 | Rezdiffra |
| Dexcom, INC. | $121.16 | 2023 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $73.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.85 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $67.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $57.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.68 | 2024 | Jardiance |
| Gilead Sciences, INC. | $34.01 | 2021 | |
| Amarin Pharma, INC. | $32.53 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.32 | 2021 | |
| Merck Sharp & Dohme LLC | $29.09 | 2021 | |
| Glaxosmithkline, LLC. | $15.18 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Pullee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.